PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23533264-0	2013	Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.	cabozantinib	12-24	ret proto-oncogene	Homo sapiens	42-45	
23533264-5	2013	We report preliminary data for the first three patients treated with the RET inhibitor cabozantinib on a prospective phase II trial for patients with RET fusion-positive NSCLCs (NCT01639508).	cabozantinib	87-99	ret proto-oncogene	Homo sapiens	73-76	
23533264-5	2013	We report preliminary data for the first three patients treated with the RET inhibitor cabozantinib on a prospective phase II trial for patients with RET fusion-positive NSCLCs (NCT01639508).	cabozantinib	87-99	ret proto-oncogene	Homo sapiens	150-153